Immunovia AB (publ)

Financial Performance

• Net sales for Q1 2026 were 374 KSEK, compared to 139 KSEK in Q1 2025.
• Operating loss was -18.4 MSEK, compared to -18.9 MSEK in the first quarter of 2025.
• Cash flow from operating activities was -20.9 MSEK, an improvement from -24.4 MSEK in Q1 2025.
• Cash and cash equivalents at the end of the period totaled 56.1 MSEK (37.7 MSEK).
• The cash…